The Acetaminophen/Caffeine combination is used in areas where short-term symptom management is appropriate, applied across domains where additional supportive care is needed. It is relevant for easing mild to moderate pain and fever.

---

This medication is commonly used across conditions presenting with acute episodes or recurrent manifestations, providing supportive relief when symptoms interfere with routine activities. It is applied in managing symptoms related to heightened physiological activity, such as tension-type headaches and the non-severe phase of migraine, and is also used for localized discomfort including toothache, period pain (dysmenorrhoea), and various musculoskeletal aches.

The combination plays a role in managing symptoms related to systemic discomfort, specifically the cluster of elevated body temperature and generalized body aches that often appear suddenly during colds or influenza. The overall goal is to maintain a sense of stability when symptoms are more noticeable.

“The primary therapeutic aim of this combination is to assist patients in coping more steadily with the difficult episodes of pain and fever that interrupt daily functioning.”

---

Quick Fact: Relief for Acute Discomfort

The combination is relevant when multiple symptoms occur together, helping to ease the overall symptom burden when patients experience headache, muscular aches, and feverishness concurrently. It contributes to improved comfort during periods of heightened symptoms.

Regulatory References

1. Health Products Regulatory Authority (HPRA) of Ireland

Dolfin is officially indicated for use in adults and adolescents, typically those 12 years of age or older, provided no specific contraindications are present according to regulatory labeling. Eligibility for the medicine is strictly defined by status, age, and pre-existing health conditions.

Populations Who Must Not Use Dolfin

Use is contraindicated (strictly prohibited) in individuals with:

• Known hypersensitivity or allergy to Acetaminophen (Paracetamol), Caffeine, or any other component in the tablet.
• A diagnosis of severe hepatic impairment or active liver disease.
• The concurrent use of any other medicine containing Acetaminophen (Paracetamol).

Restricted and Conditional Use

Use is formally not recommended for the following populations:

• Children under 12 years of age, as safety and efficacy are generally not established in this group.
• Individuals who are breastfeeding (lactation), as regulatory documents advise against it.
• Use during pregnancy, particularly the third trimester, is also not recommended.

Eligibility is restricted and requires caution in patients with severe renal impairment, chronic alcoholism, or pre-existing severe cardiovascular conditions, such as uncontrolled hypertension or arrhythmias.

The official interaction profile for Dolfin (Acetaminophen/Caffeine) is structured around managing the drug's metabolic pathways and its stimulant component, based on regulatory documentation.

Contraindicated Combinations and Mandatory Restrictions

Regulatory documents establish formal prohibitions against certain co-administered substances. The product must not be taken with any other medicine containing Paracetamol or Acetaminophen to prevent accidental overdose. Due to the caffeine component, co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated because of the risk of an acute hypertensive episode. The combination with Fezolinetant is also prohibited, as the caffeine component may increase its exposure via metabolic enzyme inhibition.

Pharmacokinetic and Metabolic Interactions

Substances that affect absorption rate include Metoclopramide and Domperidone, which may increase the speed of Acetaminophen absorption. Conversely, Cholestyramine reduces the rate of absorption and requires the Dolfin product to be administered at least one hour prior to its intake. Prolonged, regular daily use of the Acetaminophen component may enhance the anticoagulant effect of Warfarin and related Coumarin derivatives, which may require medical monitoring. Drugs that induce hepatic enzymes, such as certain Barbiturates, increase the risk of hepatotoxicity.

Interactions with Substances

Severe liver damage is officially documented as a risk when the Acetaminophen component is used concurrently with the consumption of three or more alcoholic drinks per day. Furthermore, excessive intake of dietary caffeine should be avoided to limit additive stimulant effects from the drug's caffeine content. The risk of toxicity is heightened in populations with severe hepatic impairment.

Dolfin, chemically dosulepin, operates as a reuptake inhibitor that targets the central nervous system. Its primary molecular interaction is the non-covalent binding and inhibition of the noradrenaline transporter (NAT) and the serotonin transporter (SERT), exhibiting equipotent affinity for both. This transporter blockade prevents the reuptake of the neurotransmitters noradrenaline (NE) and 5-hydroxytryptamine (5-HT) from the synaptic cleft into the presynaptic neuron. Consequently, the concentration and availability of NE and 5-HT are increased within the central synapses, leading to enhanced neurotransmission via respective postsynaptic receptors. The active metabolite, northiaden, also contributes to NE and 5-HT reuptake inhibition.

Simultaneously, the molecule acts as a non-selective antagonist at several other neuroreceptors, including histamine H1, muscarinic acetylcholine, and specific 5-HT receptor subtypes, notably the 5-HT2A receptor. Binding to H1 receptors modulates histaminergic signaling. Antagonism at 5-HT2A receptors, which are Gi/ Go-coupled and typically decrease dopamine release upon activation, results in a modification of the serotonergic pathway. This composite molecular profile modulates monoaminergic and cholinergic system activity across multiple central neuronal pathways, resulting in system-level physiological changes including altered autonomic function and somnolence.

Dolfin, an oral fixed-dose combination product containing Acetaminophen and Caffeine, is used for short-term symptomatic relief. The general principle of administration is defined by specific quantitative limits and time intervals.

Administration Principles and Frequency

The medication is administered via the oral route using the tablet dosage form. Tablets are to be swallowed whole with water and are not to be crushed or chewed. The medicine may be taken with or without food.

• Dosing Interval: A minimum of 4 hours must elapse between doses.
• Daily Limit (Adults): The maximum daily intake is limited to eight tablets in a 24-hour period (equivalent to 4000 mg of Acetaminophen).
• Duration of Use: The protocol for this product is structured for short-term use, generally not exceeding three to five consecutive days.

Dose Adjustments and Procedural Constraints

Usage involves specific considerations related to patient health status and co-administration.

1. Population-Specific Modifications: Dosing is modified for specific patient populations. For individuals with known hepatic or renal impairment, the dosage is reduced or the interval between doses is prolonged. For adolescents aged 12 to 15, the maximum daily allowance is restricted to four tablets in 24 hours.

2. Co-Administration Constraint: The product is not to be taken concurrently with any other product that contains Acetaminophen (Paracetamol). This restriction ensures that the cumulative daily limit of the primary ingredient is not exceeded.

The usage framework is based on managing the timing and quantity of the medication according to established specifications, without exceeding the maximum cumulative dose.

Research Evidence / Overview of Studies for Dolfin

Overview of the Analgesic Adjuvant Research

The clinical evaluation of the Dolfin combination was evaluated in short-term, randomized controlled trials (RCTs) and systematic reviews. This type of research was conducted during periods of increased symptom activity, exploring short-term changes in patient-reported outcomes related to physical discomfort. The studies were designed to examine the measured symptom patterns when the inclusion of caffeine was compared to the analgesic component alone or a placebo. Findings reported from systematic reviews and meta-analyses contribute to the broader evidence landscape. The research describes the study designs and monitored how symptoms evolved in the observed populations, using methods relevant in evidence describing how symptoms are measured.

---

Evidence for Use in Conditions Characterized by Episodic Symptoms

Research examined outcomes related to physical discomfort in conditions characterized by fluctuating or episodic manifestations, specifically tension-type headache (TTH) and acute migraine attacks.

• Study Focus: The trials were typically conducted during episodes where symptoms become more noticeable, focusing on outcomes such as the rate of achieving pain-free status and outcomes reflecting daily functioning or activity level within a few hours of administration.
• Uncertainty: Much of the evidence was observed in studies that may have included a third active ingredient (aspirin) alongside acetaminophen and caffeine. This may limit the direct evidence for the dual-combination product. Furthermore, the findings reflect group patterns and research does not determine whether an individual will respond similarly.

---

Evidence for Use in Acute Pain Scenarios

The combination was observed in RCTs in various acute pain models, such as those related to dental extraction or menstrual pain (dysmenorrhoea). Findings from these models describe patterns observed in the studies, where time-to-measured-symptom-change was compared to the analgesic component alone. For the use of Dolfin in situations involving fever, the regulatory evidence is largely informed by data related to the acetaminophen component. Dedicated research specifically examining the influence of the caffeine component on outcomes related to physiological strain, such as temperature reduction, is less common.

---

Limitations of Long-Term Studies and Follow-up

Follow-up durations were limited in these studies, often focusing on single-dose effects observed over a period of four to six hours. There is limited information for long-term outcomes, and long-term effects are not fully established. The research provides context, but study results reflect the specific conditions under which they were conducted and do not predict whether an individual will respond similarly when used over extended periods. Evidence remains limited for the combination's use in pediatric populations.

Key Studies & References

1. Health Products Regulatory Authority (HPRA) of Ireland: Product Information Leaflet (PIL) or Summary of Product Characteristics (SmPC) for combination analgesics (Generic Monograph)
2. Guideline: Acute Pain Management in Adults (Reference for specific acute pain models, e.g., dental pain)

Common questions about Dolfin (FAQ)

Q: What is Dolfin used for?

Dolfin is a prescription medication approved to treat the symptoms of moderate-to-severe chronic conditions, as indicated by the drug's official regulatory labeling. Your healthcare provider determines if this medication is appropriate for your specific condition.

Q: How should I store Dolfin?

Dolfin should be stored at room temperature, away from moisture and heat. It is important to keep the medication in its original container. Check the product label for specific temperature and storage instructions provided by the manufacturer.

Q: Can Dolfin be taken with other medicines?

The potential for interactions between Dolfin and other medicines, including prescription, over-the-counter drugs, and supplements, should be reviewed with a healthcare professional. Information on specific interactions is typically detailed in the official product information.

How to Store and Dispose of Dolfin?

The storage and disposal of Dolfin tablets are governed by official requirements to maintain drug stability and prevent accidental harm.

Storage and Handling Constraints

The product must be stored at controlled room temperature, generally between 20 C and 25 C (68 F and 77 F), with excursions permitted up to 30 C. The container should be kept tightly closed to protect the medicine from moisture and excessive heat. It is advised in regulatory labeling not to refrigerate or freeze the tablets. The use of the product is not guaranteed past its expiration date.

Mandatory Safety and Disposal

The most important safety rule is the mandatory instruction: KEEP OUT OF THE REACH OF CHILDREN, as the package contains enough drug to cause serious harm. Disposal of unused or expired tablets must be done in accordance with local requirements. The best method is to use a drug take-back program. Tablets should not be disposed of in wastewater (e.g., flushed down the toilet).